Tumour heterogeneity in the clinic.
Tumour heterogeneity in the clinic.
复制标题
DOI：
10.1038/nature12627
复制
发表时间：
2013-09-19
期刊：
影响因子：
64.8
通讯作者：
Siu LL
中科院分区：
文献类型：
--
作者：
Bedard PL;Hansen AR;Ratain MJ;Siu LL
肿瘤学的最新治疗进展是通过识别患者之间的肿瘤基因型变异（称为患者间异质性）来推动的，这种变异可以预测患者对靶向治疗的反应。同一患者中具有独特基因组的癌细胞亚群可能存在于肿瘤的不同地理区域，或者随着时间的推移而进化，称为肿瘤内异质性。测序技术可用于在诊断时表征肿瘤内异质性、在治疗期间监测克隆动态以及在疾病进展期间识别临床耐药性的出现。患者间和肿瘤内的遗传异质性可能会给使用这些数据的临床试验的设计带来挑战。
Recent therapeutic advances in oncology have been driven by the identification of tumour genotype variations between patients, called interpatient heterogeneity, that predict the response of patients to targeted treatments. Subpopulations of cancer cells with unique genomes in the same patient may exist across different geographical regions of a tumour or evolve over time, called intratumour heterogeneity. Sequencing technologies can be used to characterize intratumour heterogeneity at diagnosis, monitor clonal dynamics during treatment and identify the emergence of clinical resistance during disease progression. Genetic interpatient and intratumour heterogeneity can pose challenges for the design of clinical trials that use these data.